$BJDX

HRT FINANCIAL LP sold $49K of BJDX

HRT FINANCIAL LP sold 34,938 shares of Bluejay Diagnostics, Inc. (BJDX) at $1.40 on 2026-07-10.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jul 13, 2026, 7:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 13, 2026, 7:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BJDX
Neutral
medium confidence
Mentioned
$BJDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BJDXNeutralLow
01

Why it matters

The newest fact is the reported open-market sale by a 10% owner at a specified price and share count; it may influence short-term sentiment but does not change operating outlook based on the provided text.

02

Market read

Traders may monitor for follow-on insider activity or interpret the sale as mild negative sentiment, but there is no new fundamental catalyst in the text.

03

What to watch

No 10b5-1 plan is stated, but the article also lacks context on total holdings, prior sales cadence, or whether the sale was part of broader portfolio rebalancing.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-13, sale dated 2026-07-10

Background

This is an SEC Form 4 insider transaction disclosure for Bluejay Diagnostics, Inc. (BJDX).

Company-level read

Ticker impact

$BJDXNeutralMedium confidence
Context

HRT Financial LP, a 10% owner, filed a Form 4 selling 34,938 BJDX shares at $1.40 on 2026-07-10.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven.

Evidence & confidence

The filing is a routine insider sale with no 10b5-1 plan and no accompanying company-specific news (earnings, guidance, trials, deals). Size is moderate, so impact is usually contained.

Market effects

No sector read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The sale may be liquidity-driven and not a bearish signal, especially since the filing provides no rationale or linkage to company performance.

Key entities

  • Bluejay Diagnostics, Inc.

    Subject of the Form 4 insider sale disclosure (BJDX).

  • HRT Financial LP

    10% owner who sold 34,938 shares in an open-market transaction.

  • SEC Form 4

    Primary-source insider transaction report filed on 2026-07-13.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 For Immediate Release Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock. SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Towar

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics (NASDAQ:BJDX) announced baseline clinical data from its SYMON-II study, evaluating IL-6 as a biomarker for 28-day mortality risk in sepsis patients. The study included 777 patients, with an 18% mortality rate. The company aims to use this data to support a regulatory submission for its Symphony IL-6 Test, which is not yet FDA-approved.

$JNJMedAI 8/10

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

Johnson & Johnson (JNJ) received CE Marking for ACUVUE OASYS MAX 2-Week contact lenses. GSK (GSK) expanded Shingrix approval in Japan. Axogen (AXGN) to acquire BioCircuit for $200M. Femasys (FEMY) partnered with CapexMD for fertility financing. EpilepsyGTx collaborated with Viralgen (BAYN.DE) for gene therapy. HCW Biologics (HCWB) partnered with Akron Biotech. Bluejay Diagnostics (BJDX) teamed with Lovell for federal market access. Transgene (TNG.PA) expanded partnership with ProBioGen. Oncolyti